Pseudomonas Aeruginosa: Modern Realities of Antibiotic Therapy

L.A. Kharchenko

Abstract


The article presents an analysis of antibiotic resistance to Pseudomonas aeruginosa. Our own observations on Pseudomonas aeruginosa resistance to antipseudomonal antibiotics, carried out in Ukrainian medical center of intensive care for sepsis, are provided.
All investigated strains were multiresistant, and patients, which were surveyed, previously were for a long time in various hospitals.
To date, only colomycin is a drug, to which Pseudomonas aeruginosa has a high antibiotic sensitivity.


References


Dalfino L. et al. High-dose, extended-interval colistin admi­nistration in critically ill patients: is this the right dosing strategy? A preliminary study / L. Dalfino et al. // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. — 2012. — Vol. 54, № 12. — P. 1720-1726.

Couet W. et al. Colistin pharmacokinetics: the fog is lifting / W. Couet et al. // Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. — 2012. — Vol. 18, № 1. — P. 30-39.

Calfee D.P. Crisis in hospital-acquired, healthcare-associated infections / D.P. Calfee // Annual review of medicine. — 2012. — Vol. 63. — P. 359-371.

Plachouras D. et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria / D. Plachouras et al. // Antimicrobial agents and chemotherapy. — 2009. — Vol. 53, № 8. — P. 3430-3436.

Bergen P.J. et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic mo­del / P.J. Bergen et al. // Antimicrobial agents and chemotherapy. — 2011. — Vol. 55, № 12. — P. 5685-5695.

Mena K.D. & Gerba C.P. Risk assessment of Pseudomonas aeruginosa in water / K.D. Mena, C.P. Gerba // Reviews of Environmental Contamination and Toxicology. — 2009. — Vol. 201. — P. 71-115.

Park Y.S. et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems / Y.S. Park et al. // The Journal of hospital infection. — 2011. — Vol. 79, № 1. — P. 54-58

Blanc D.S. Francioli P. & Zanetti G. Molecular Epidemiology of Pseudomonas aeruginosa in the Intensive Care Units — A Review / D.S. Blanc, P. Francioli, G. Zanetti // The Open Microbiology Journal. — 2007. — Vol. 1. — P. 8-11.

Boyer A. et al. Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients’ environment / A. Boyer et al. // Critical Care (London, England). — 2011. — Vol. 15, № 1. — P. R55.

Agodi A. et al. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients / A. Agodi et al. // Intensive Care Medicine. — 2007. — Vol. 33, № 7. — P. 1155-1161.

Poole K. Pseudomonas aeruginosa: resistance to the max / K. Poole // Frontiers in Microbiology. — 2011. — Vol. 2. — P. 65.

Aloush V. et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact / V. Aloush et al. // Antimicrobial Agents and Chemotherapy. — 2006. — Vol. 50, № 1. — P. 43-48.

Giske C.G. et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli / C.G. Giske et al. // Antimicrobial agents and chemotherapy. — 2008. — Vol. 52, № 3. — P. 813-821.

Paterson D.L. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy / D.L. Paterson // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. — 2008. — Vol. 47, suppl 1. — P. S14-20.

Magiorakos A.-P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance / ­A.-P. Magiorakos et al. // Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. — 2012. — Vol. 18, № 3. — P. 268-281.

Peña, C. et al. Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients / C. Peña et al. // European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology. — 2009. — Vol. 28, № 5. — P. 519-522.

Rossolini G.M. & Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa / G.M. Rossolini, E. Mantengoli // Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. — 2005. — Vol. 11, suppl. 4. — P. 17-32.

Kumar A. et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study / A. Kumar et al. // Critical care medicine. — 2010. — Vol. 38, № 8. — P. 1651-1664.

Traugott K.A. et al. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum / K.A. Traugott et al. // Pharmacotherapy. — 2011. — Vol. 31, № 6. — P. 598-608.

Pankuch G.A. et al. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii / G.A. Pankuch et al. // Antimicrobial agents and chemotherapy. — 2008. — Vol. 52, № 1. — P. 333-336.

Bergen P.J. et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula / P.J. Bergen et al. // Antimicrobial agents and chemotherapy. — 2011. — Vol. 55, № 11. — P. 5134-5142.

Gunderson, B.W. et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model / B.W. Gunderson et al. // Antimicrobial agents and chemotherapy. — 2003. — Vol. 47, № 3. — P. 905-909.

Llanes C. et al. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously / C. Llanes et al. // Antimicrobial Agents and Chemotherapy. — 2004. — Vol. 48, № 5. — P. 1797-1802.

Nicasio A.M. et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia / A.M. Nicasio et al. // Antimicrobial Agents and Chemotherapy. — 2009. — Vol. 53, № 4. — P. 1476-1481.

Talbot G.H. et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America / G.H. Talbot et al. // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. — 2006. — Vol. 42, № 5. — P. 657-668.




DOI: https://doi.org/10.22141/2224-0586.1.64.2015.79629

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта